MNMD

Mind Medicine (MindMed) Inc

Add to Watchlist

Advanced Chart

9.980

+0.13(1.320%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.020

Open

9.805

VWAP

9.94

Vol

95.53K

Mkt Cap

722.32M

Low

9.805

Amount

949.41K

EV/EBITDA(TTM)

Total Shares

71.87M

580.52M

EV/OCF(TTM)

P/S(TTM)

Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

10 Analyst Rating

160.52% Upside

Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 26.00 USD with a low forecast of 16.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

160.52% Upside

Current: 9.980

Low

16.00

Averages

26.00

High

55.00

160.52% Upside

Current: 9.980

Low

16.00

Averages

26.00

High

55.00

Oppenheimer

Jay Olson

Outperform

initiated

$25

2025-08-04

Reason

Oppenheimer

Jay Olson

Price Target

$25

2025-08-04

initiated

Outperform

Reason

Oppenheimer analyst Jay Olson resumed coverage of Mind Medicine with an Outperform rating and $25 price target. The firm previously had no rating on the shares. The analyst has "high conviction" that the company's lead asset MM120 will "revolutionize" neuropsychiatry with its potential to drive durable remission. MM120 has a "unique" clinical profile with its less-intense but longer psychedelic experience compared to other approaches, the analyst tells investors in a research note.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$55

2025-03-07

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$55

2025-03-07

Reiterates

Strong Buy

Reason

Baird

Joel Beatty

Buy

Maintains

$27 → $16

2025-03-07

Reason

Baird

Joel Beatty

Price Target

$27 → $16

2025-03-07

Maintains

Buy

Reason

Baird lowered the firm's price target on Mind Medicine to $16 from $27 and keeps an Outperform rating on the shares. The firm noted both Phase 3 trials of MM120 for GAD are enrolling witht he first results expected in the first half of 2026.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$55

2025-01-31

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$55

2025-01-31

Reiterates

Strong Buy

Reason

Evercore ISI Group

Gavin Clark-Gartner

Buy

Initiates

$23

2025-01-28

Reason

Evercore ISI Group

Gavin Clark-Gartner

Price Target

$23

2025-01-28

Initiates

Buy

Reason

Chardan Capital

Rudy Li

Strong Buy

Initiates

$20

2024-12-20

Reason

Chardan Capital

Rudy Li

Price Target

$20

2024-12-20

Initiates

Strong Buy

Reason

Chardan initiated coverage of Mind Medicine with a Buy rating and $20 price target. The firm cites the potential of the company's lead asset MM120 for the treatment of generalized anxiety disorder and major depressive disorder for its Buy rating. Its thesis assumes MM120 will report positive data in 2026 and deliver a solid commercial launch with over $1B in peak sales. Chardan expects the sentiment on the shares to continue to improve moving into 2025 with multiple key catalyst events.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Mind Medicine (MindMed) Inc (MNMD.O) is -5.03, compared to its 5-year average forward P/E of -6.88. For a more detailed relative valuation and DCF analysis to assess Mind Medicine (MindMed) Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.88

Current PE

-5.03

Overvalued PE

-0.59

Undervalued PE

-13.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.43

Current EV/EBITDA

-3.83

Overvalued EV/EBITDA

11.22

Undervalued EV/EBITDA

-40.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00